ALUPENT
LOE ApproachingNDAORALSYRUP
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an oral syrup small-molecule product approved in 1975 by Boehringer Ingelheim. The specific indication and mechanism of action are not publicly detailed in available data. This legacy product represents a mature small-molecule therapeutic in the oral syrup delivery format.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals a transitional product team focused on retention and generic preparation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALUPENT roles focus on defending market share and managing the LOE transition rather than growth. Career opportunity is limited by zero linked job postings and mature product status, making this assignment best suited for experienced professionals managing product sunset.
Brand ManagerField Sales Representative
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.